16 years of historical data (2009–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Scinai Immunotherapeutics Ltd. trades at 0.1x earnings, 73% below its 5-year average of 0.6x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 99%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.0B | $3M | $2M | $6M | $33M | $31M | $76M | $31M | $27M | $11M | $10M |
| Enterprise Value | $3.0B | $3M | $18M | $13M | $45M | $49M | $93M | $36M | $6M | $7M | $2M |
| P/E Ratio → | 0.15 | 0.56 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4607.73 | 4.11 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.07 | 0.27 | — | — | 33.78 | — | — | — | 1.67 | 1.70 | 1.21 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.29 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | 17.85 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 21.52 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Scinai Immunotherapeutics Ltd. earns an operating margin of -1312.8%. Return on equity of 177.4% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -88.1% | -88.1% | — | — | — | — | — | — | — | — | — |
| Operating Margin | -1312.8% | -1312.8% | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | 728.9% | 728.9% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 177.4% | 177.4% | — | — | -835.6% | — | — | -600.0% | -87.0% | -31.2% | -40.7% |
| ROA | 31.0% | 31.0% | -29.2% | -19.6% | -33.0% | -5.4% | -102.3% | -90.6% | -63.5% | -25.9% | -34.1% |
| ROIC | -61.1% | -61.1% | -86.5% | -89.5% | -62.1% | 29.5% | — | — | — | -178.8% | -240.5% |
| ROCE | -63.2% | -63.2% | -48.0% | -40.7% | -79.6% | 17.7% | -89.9% | -93.7% | -47.0% | -35.1% | -40.2% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $122000 ($2M total debt minus $2M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.21 | — | — | 29.77 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 7.60 | — | — | — | — | — |
| Net Debt / Equity | — | 0.01 | — | — | 12.08 | — | — | — | -1.27 | -0.61 | -1.00 |
| Net Debt / EBITDA | — | — | — | — | — | 6.53 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -6.00 | -6.00 | -1216.44 | -2.19 | -3.23 | 6.54 | -5.30 | -5.45 | -332.39 | -30890.00 | -371746.74 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.32x means Scinai Immunotherapeutics Ltd. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 6.15x to 1.32x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.32 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 3.86 | 3.53 | 10.94 | 19.01 | 21.74 |
| Quick Ratio | 1.32 | 1.32 | 3.06 | 6.15 | 7.30 | 0.17 | 3.86 | 3.53 | 10.94 | 19.01 | 21.74 |
| Cash Ratio | 1.09 | 1.09 | 2.74 | 6.02 | 7.11 | 0.15 | 3.82 | 3.48 | 10.37 | 18.42 | 20.89 |
| Asset Turnover | — | 0.05 | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | 101629.33 | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 120.37 | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Scinai Immunotherapeutics Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 100.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 179.1% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $806368 | $390657 | $188519 | $141144 | $110815 | $81663 | $65355 | $50258 | $33774 | $26381 |
Compare SCNI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| SCNIYou | $3B | 0.1 | — | — | -88.1% | -1312.8% | 177.4% | -61.1% | — |
| BNTX | $28B | -33.7 | — | — | 80.3% | -47.8% | -3.4% | -10.5% | — |
| MRNA | $21B | -5.8 | — | — | 54.2% | -123.3% | -28.8% | -27.0% | — |
| SMMT | $13B | -11.5 | — | — | — | — | -206.1% | -163.4% | — |
| PCVX | $8B | -11.0 | — | — | — | — | -25.6% | -24.7% | — |
| CDTX | $7B | -8.3 | — | — | 100.0% | -13811.9% | -219.0% | — | — |
| NVAX | $2B | 3.9 | 3.7 | — | 93.5% | 40.3% | — | — | 0.5 |
| VIR | $1B | -2.9 | — | — | 82.9% | -682.7% | -45.7% | -40.3% | — |
| CVAC | $1B | 6.5 | 3.1 | 12.6 | 80.2% | 33.2% | 26.7% | 65.0% | 0.2 |
| VALN | $963M | -55.3 | 26.3 | — | 41.9% | 7.9% | -7.9% | 4.5% | 6.6 |
| CRMD | $559M | -23.8 | — | — | 92.7% | -51.4% | -23.2% | -46.8% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 16 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SCNI stacks up against sector leader BioNTech SE.
Start ComparisonScinai Immunotherapeutics Ltd.'s current P/E ratio is 0.1x. The historical average is 0.6x.
Scinai Immunotherapeutics Ltd.'s return on equity (ROE) is 177.4%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -16.5%.
Based on historical data, Scinai Immunotherapeutics Ltd. is trading at a P/E of 0.1x. Compare with industry peers and growth rates for a complete picture.
Scinai Immunotherapeutics Ltd. has -88.1% gross margin and -1312.8% operating margin.